MEDGm review

The pricing promise here is the flat one: the seller states outright that the price never increases even as the dose goes up, which suits a patient expecting to titrate and is the least economical structure there is for a reader who intends to stay small. A quarter dose is billed exactly like a full one. Getting to any figure at all takes a sixteen-screen intake ending in a name, an email address and a phone number, and the figure that then appears carries a welcome coupon applied automatically — remove the coupon and the panel rewrites itself to a rate a hundred and twenty dollars higher, which is what every renewal after the first will cost. That sits awkwardly against the same page's promise that the price never increases and there are no hidden fees. Four dispensing pharmacies are named in the terms with full street addresses, which is more than most sellers disclose. Brand-name products have cards on the GLP-1 page and are never sold: every link on them leads to the same quiz, and none of the three appears anywhere after it.

Vs median

$127/mo above the $172 median across the 254 of 393 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

September 2026

MEDGm dispenses through a RedRock · Health Warehouse · Precision Medicine · Triad Rx — 503A or 503B, not stated per pharmacy facility. No bloodwork is required before you start. A clinician review is included in the price.

MEDGm sells compounded semaglutide as an injection and as an oral dissolving tablet, and compounded tirzepatide as an injection, with a prepay ladder on each. Its own questions say the price never increases even as the dose goes up, so a reader taking a quarter of a dose pays what a reader taking a full one pays — the flat structure, stated plainly. Nothing is priced until a sixteen-screen intake ending in a name, an email address and a phone number has been completed, and the figure that then appears carries an automatically applied welcome coupon: $179 for semaglutide, which becomes $299 the moment the coupon is removed, and the same shape on the oral tablet and on tirzepatide. Four dispensing pharmacies are named in the terms with full street addresses, which is more than most sellers here disclose, though the site does not say which is a 503A and which a 503B, nor which fills which order. Brand-name Zepbound, Wegovy and Ozempic have cards on the GLP-1 page and are never sold: every link on them leads to the same quiz and none of the three appears anywhere after it.

ONE PRICE AT EVERY DOSE, so a quarter dose is billed exactly like a full one — the structure that suits a titrating patient and costs a microdoser the most

• NOTHING IS PRICED UNTIL A SIXTEEN-SCREEN INTAKE IS FINISHED, ending in a name, an email address and a phone number
• The $179 shown on the way in is a first-month rate from an automatically applied coupon; removing it rewrites the panel to $299
• Its own questions promise the price never increases and there are no hidden fees, on a plan that goes from $179 to $299 at the first renewal
• The twelve-month plan renews for another full upfront charge, up to ten days early, and nothing is refundable once taken
• The funnel prints an approval, a hundred percent success probability and a countdown before payment and before any clinician has seen the intake
• Zepbound, Wegovy and Ozempic are advertised with membership cards and never sold — every link goes to the quiz and none appears after it
• The site does not say which of the four pharmacies is a 503A and which a 503B, nor which fills a given order, and names no clinician
• No milligram is published anywhere
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

MEDGm is one of 393 low-dose GLP-1 programs we track, and 254 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• Low dose vs full dose
• What microdosing GLP-1 costs
• What the evidence actually shows
• What a flat price costs at a low dose
• The true annual cost of a plan